Roche Announces Opening of New R&D Building
Earlier today Roche announced the opening of their new R&D office in Basel, Switzerland.
The building, which represents an investment of CHF 250 million, will be used to study and develop pharmaceutical formulations for new active ingredients, as well as produce supplies for global clinical trials.
Headquartered in Basel, Roche is a leader in research-focused healthcare with collective strengths in pharmaceuticals and diagnostics.
Commenting on the opening of the new facility, Roche Group CEO, Severin Schwan, said “finding the safest and most efficient formulation for an active ingredient is a key part of the drug development process”. “Functions from the entire pharmaceutical value-chain are located in Basel. This investment further strengthens the role of Basel headquarters and as a global centre for research and development,” Schwan added.
Matthias M. Baltisberger, Head of Roche’s Basel Site, noted that “Basel is a global centre of excellence for innovative formulation processes. By expanding our capacity in this field, we will be able to respond even more effectively to patients’ needs and make medication easier to use.” “This will be the first time in Roche’s history that employees in technical research and development will actually be sharing the same working area. By working together in close proximity they will be able to collaborate even closer on this pivotal aspect of drug development” he added.
The new R&D building is the initial step in renovating the site along Wettsteinallee. High quality architecture in the Bauhaus tradition has been the hallmark of Roche’s buildings since the early 20th century.